Corcept Therapeutics Logo
US2183521028
529882
CORT

Corcept Therapeutics

Forecast

The analysts' average price target is €121.03 (+108.64%). The median is €136.70 (+135.65%).

Buy
  14
Hold
  9
Sell
  3

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Corcept Therapeutics raises guidance after strong quarter and record volume

    Corcept reports a massive jump in profit and an increase in revenue on record trading volume, prompting management to sharply raise its full-year forecast. The new oncology drug Lifyorli is expected to deliver further growth in the medium term. Management is targeting annual sales of up to $5 billion by 2030. » More on finanzen.net


  • Corcept Therapeutics reaches new all-time high after strong quarterly results

    The stock of Corcept Therapeutics rose to an all-time high of $122.50 and is currently trading at $121.31, corresponding to a market capitalization of $13.13 billion. In the second quarter of 2026 the company reported revenue of $256.1 million (+32% year-on-year) and raised its full-year guidance to $1.1–1.2 billion. Analysts responded with price-target increases and positive assessments, while InvestingPro currently rates the stock as overvalued relative to its fair value. » More on de.investing.com


  • Corcept Therapeutics reaches 52-week high at $95.18

    Shares of Corcept Therapeutics rose to a 52-week high of $95.18, gaining 152% over the past six months and 163% year-to-date. The company has resubmitted the New-Drug-Application for Relacorilant to the FDA for the treatment of Cushing’s syndrome; the review is expected to take six months. At ASCO, Corcept presented data from the phase‑3 ROSELLA study showing a 35% reduction in risk of death with Lifyorli (Relacorilant) plus nab‑paclitaxel. First-quarter 2026 revenues of about $165 million were below consensus, but analysts still raised price targets and reiterated buy ratings. » More on de.investing.com


  • Corcept resubmits approval application for relacorilant to treat Cushing's syndrome to FDA

    Corcept resubmitted the New Drug Application for relacorilant to the FDA and included additional analyses of the originally requested data. The company expects a six-month review period; the submission is based on data from the GRACE study, the phase III GRADIENT study, a long-term extension and earlier development phases. According to Corcept, relacorilant improves symptoms of Cushing's syndrome without certain side effects, received orphan-drug status and is also already FDA-approved as Lifyorli for platinum-resistant ovarian cancer. Investors reacted positively; the stock is up about 141% year-to-date and the company has a market capitalization of $8.79 billion. » More on de.investing.com


  • Corcept shows phase‑3 data: relacorilant plus nab‑paclitaxel extends survival in ovarian cancer

    In the ROSELLA trial, relacorilant (Lifyorli) in combination with nab‑paclitaxel reduced the risk of death by 35% versus nab‑paclitaxel alone (hazard ratio 0.65; p=0.0004) and increased median overall survival to 16.0 versus 11.9 months. A biomarker test was not required; subgroups with a short taxane‑free interval showed similar effects. Lifyorli was approved by the FDA in March 2026 for the combination therapy in platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. The stock is up 96% so far in 2026 (week +13.6%); frequent adverse events and 35% serious adverse events in the combination group were reported. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Corcept Therapeutics has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Corcept Therapeutics had revenue of €300.59M and net profit of €111.93M

(EUR) September 2026
YoY
Revenue 300.59M 69.89%
Gross profit 296.52M 71.38%
Net profit 111.93M 567.83%
EBITDA 107.12M 699.66%

Fundamentals

Metric Value
Market capitalization
€6.76B
Number of shares
109.44M
52-week high/low
€115.18 - €26.12
Dividends No
Beta
0.45
P/E ratio
45.19
PEG ratio
0.90
P/B ratio
8.67
P/S ratio
7.70

Company profile

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Name
Corcept Therapeutics
CEO
Joseph K. Belanoff
Headquarters Redwood City, ca
USA
Website
Sector
Health Care
Industry
Pharmaceuticals
IPO
04/14/2004
Employees 730

Ticker symbols

Exchange Symbol
NASDAQ
CORT
London Stock Exchange
0I3Q.L
Frankfurt
HTD.F
DĂĽsseldorf
HTD.DU
London
0I3Q.L
SIX
HTD.SW
MĂĽnchen
HTD.MU
Milan
1CORT.MI
🍪

Parqet  uses cookies. Learn more